Integration of RNA Trans-Editase-Based Correction Platform and Tissue-Selective LNP Delivery Technology

Algonomics, a company specializing in the development of RNA-based gene therapeutics, and Surginex, a specialist in lipid nanoparticle (LNP) delivery systems, announced on April 9 that they have signed a “strategic memorandum of understanding (MOU) for the development of next-generation precision-targeted RNA gene therapeutics based on LNP technology.”

Algonomics Company Logo Image. Algonomics

Algonomics Company Logo Image. Algonomics

View original image

The core of this agreement is the combination of Algonomics’ RNA trans-editase-based correction platform and Surginex’s tissue-selective LNP delivery technology. The companies aim to increase target cell selectivity and in vivo delivery efficiency, with the goal of expanding treatment to disease areas that have been difficult to address with conventional therapeutics.


Algonomics is a company focused on developing gene therapeutics based on RNA editing technology. It possesses both multiplex RNA editing technology and a circular RNA platform. Circular RNA is characterized by slower degradation and more sustained protein expression compared to linear RNA, making it a promising candidate for next-generation RNA therapeutics.


Surginex has developed LNP technology as an RNA delivery vehicle. The company has secured formulations that allow for repeated dosing and organ-specific targeting. It has also accumulated expertise in designing formulations tailored to various types of RNA molecules.


The strategy of combining gene design technology with delivery technology is a common approach in global RNA therapeutic development. This approach is believed to enhance development success rates and accelerate progress by overcoming the limitations of each individual technology.



Lee Sungwook, CEO of Algonomics, stated, “We will expand the application scope of the RNA platform through the integration with delivery technology.” Kim Sejun, CEO of Surginex, added, “By combining the technologies of both companies, we will achieve results in the global market.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing